NEW YORK (GenomeWeb) — Celmatix said today that it has launched a new therapeutics division focused on women's health indications with high unmet need including reproductive disorders and menopause.
Called Celmatix Biosciences, the new division will use Celmatix's Reproductive Atlas program — which is combining biological annotations from peer-reviewed literature with genomic data associated with lifestyle, diet, environment, and reproductive outcomes — to power its drug-discovery activities.
Celmatix Biosciences' most advanced program is in premature ovarian failure and currently in the lead optimization and selection stage, Celmatix said. The unit is also conducting target discovery research in endometriosis, polycystic ovary syndrome, and — with undisclosed funding from the Bill & Melinda Gates Foundation — female contraception.
The launch of Celmatix Biosciences comes about one year after New York City-based Celmatix kicked off expansion efforts following the receipt of $4.5 million in funding from the New York City Regional Economic Development Council and New York State Department of Health approval for its Fertilome multi-gene panel test for reproductive health conditions.